LAVA-1207 is under clinical development by LAVA Therapeutics and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how LAVA-1207’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LAVA-1207 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is administered through intravenous route. The therapeutic candidate comprises single domain bi-specific antibody that acts by targeting T cell receptor of Vgamma9Vdelta2 T-cells and PSMA. It is being developed based on bi-specific gamma delta T cell engager (bsTCEs) platform and Gammabody platform.
LAVA Therapeutics overview
LAVA Therapeutics is a biotechnology company. It is engaged in developing immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon-gamma secretion and HLA-unrestricted tumor cell killing capabilities for alpha-beta-T cells advancing the development of adaptive immune responses for selected tumor targets. Lava Therapeutics licenses its V?9Vd2 T-cell immune oncology assets from the VU University Medical Center in Amsterdam. It seeks to work in partnerships or collaborations in licensing its products and proprietary technologies. The company is funded by Biox Biosciences BV, and Lupus Ventures BV. Lava Therapeutics is headquartered in s-Hertogenbosch, Noord Brabant, the Netherlands.
For a complete picture of LAVA-1207’s drug-specific PTSR and LoA scores, buy the report here.